The LECR conducts clinically oriented cancer research programs aiming at understanding how cancer cells evolve progressively and acquire aggressive and metastatic phenotype.


The LECR activities mostly focus on the molecular mechanisms by which tumour cells escape from the host immune system control, including the cytoskeleton remodeling, and how tumour cells educate and sculpt stromal cells within the tumour microenvironment to drive the construction of their own niche.
Such research activities are conducted by three research groups operating in the LECR: Tumor Microenvironment; Tumor-Stroma Interactions; and Cytoskeleton & Cancer Progression.

The LECR conducts cancer research at the interface of basic and clinical research.
The laboratory is actively involved in training PhD students and is affiliated to the doctoral school of “Cancérologie” of the University of Paris Sud.

Strategic research goals

  • Development of innovative therapeutic approaches based on the targeting of hypoxia-induced autophagy to improve the anti-tumor immune response in vivo.
  • Study of the temporal dynamic of immune cells infiltrating hypoxic tumours.
  • Investigate the role of exosomes in the cross-talk between cancer cells and their microenvironment.
  • Study the influence of hypoxic stress on miRNA regulatory machinery.
  • Investigate the role of cytoskeleton regulatory proteins, and related signalling pathways in driving tumor cell invasion and immune evasion.

Head of research unit

Since its creation in 2003, the LECR has been headed by Dr Guy Berchem (MD, PhD), hematolo-oncologist at the “Center Hospitalier de Luxembourg”.

Associate Head of research unit

Dr Bassam Janji (PhD) is the associate head of the laboratory.


Guy Berchem

M.D., Ph.D.

1A-B, rue Thomas Edison
1445 Strassen
Tel. : +352 4411-2084